Related Experiment Video
Updated: Jun 24, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Overcoming tumor drug resistance with C2-modified 10-deacetyl-7-propionyl cephalomannines: a QSAR study
Corwin Hansch1, Rajeshwar P Verma
1Department of Chemistry, Pomona College, Claremont, CA 91711, USA.
Abstract:
The microtubule-stabilizing taxanes such as paclitaxel and docetaxel are the two most important anticancer drugs currently used in clinics for the treatment of various types of cancers. However, the major common drawbacks of these two drugs are drug resistance, neurotoxicity, substrate for drug transporter P-gp, cross-resistance with other chemotherapeutic agents, low oral bioavailability, and no penetration in the blood-brain barrier (BBB). These limitations have led to the search for new taxane derivatives with improved biological activity. In the present paper, we discuss the quantitative structure-activity relationship (QSAR) studies on a series of C2-modified 10-deacetyl-7-propionyl cephalomannines (IV) with respect to their binding affinities toward beta-tubulin and cytotoxic activities against both drug-sensitive and drug-resistant tumor cells, in which resistance is mediated through either P-gp overexpression or beta-tubulin mutation mechanisms, by the formulation of five QSARs. Hydrophobicity and molar refractivity of the substituents (pi(X) and MR(X)) are found to be the most important determinants for the activity. Parabolic correlations in terms of MR(X) (eqs 2 and 4 ) are encouraging examples in which the optimum values of MR(X) are well-defined. We believe that these two QSAR models may prove to be adequate predictive models that can help to provide guidance in design and synthesis, and subsequently yield very specific cephalomannine derivatives (IV) that may have high biological activities. On the basis of these two QSAR models, 10 cephalomannine analogues (IV-21 to IV-30) are suggested as potential synthetic targets. Internal (cross-validation (q(2)), quality factor (Q), Fischer statistics (F), and Y-randomization) and external validation tests have validated all the QSAR models.
Insights
New taxane derivatives show improved anticancer activity by addressing drug resistance and toxicity. Quantitative structure-activity relationship studies identified key molecular properties for designing more effective cancer therapies.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Computational Chemistry
Background:
- Taxanes like paclitaxel are vital anticancer drugs but suffer from resistance, neurotoxicity, and poor blood-brain barrier penetration.
- These limitations necessitate the development of novel taxane derivatives with enhanced efficacy and safety profiles.
- Drug resistance mechanisms include P-glycoprotein (P-gp) overexpression and beta-tubulin mutations.
Purpose of the Study:
- To conduct quantitative structure-activity relationship (QSAR) studies on novel C2-modified cephalomannine derivatives.
- To correlate structural modifications with binding affinity to beta-tubulin and cytotoxic activity against various cancer cells.
- To identify key physicochemical properties influencing the biological activity of these taxane analogs.
Main Methods:
- Formulation of five QSAR models based on a series of C2-modified 10-deacetyl-7-propionyl cephalomannines.
- Evaluation of binding affinities toward beta-tubulin and cytotoxic activities against drug-sensitive and drug-resistant tumor cells.
- Statistical validation of QSAR models using internal (cross-validation, Q, F, Y-randomization) and external tests.
Main Results:
- Hydrophobicity (pi(X)) and molar refractivity (MR(X)) of substituents were identified as critical determinants of activity.
- Parabolic correlations with MR(X) provided well-defined optimal values, indicating specific structural requirements.
- QSAR models demonstrated predictive power for designing potent cephalomannine derivatives.
Conclusions:
- The developed QSAR models offer valuable guidance for the rational design and synthesis of novel cephalomannine derivatives.
- Optimized derivatives could overcome existing taxane limitations like drug resistance and poor bioavailability.
- Ten specific cephalomannine analogues are proposed as promising candidates for further investigation and development.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase